Study tracks pneumococcal infections in adults to sharpen vaccine strategies
NCT ID NCT03983616
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study monitored 1560 adults hospitalized with invasive pneumococcal infections (excluding meningitis) across France. Researchers collected information on infection severity, risk factors, and bacterial serotypes to understand how these infections occur and how vaccines might be better targeted. The goal was to provide data that could guide future vaccination recommendations for adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this surveillance could help refine vaccine guidelines for adults against pneumococcal infections.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot prove that any vaccine works; it only gathers data to inform future recommendations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Virologie
Limoges, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Text message nudge could save thousands from pneumonia
- Vaccine Follow-Up: how long does protection last in babies?
- French study tracks pneumococcal infections in kids after vaccine rollout
- Are hidden immune defects causing your recurring infections? new study investigates.
- New vaccine aims to shield infants from deadly pneumonia
- New vaccine strategy aims to shield lymphoma patients from deadly infections